Who to call at Citius Oncology, Inc., and when
Fundz watches for the moments Citius Oncology, Inc. starts buying, and tells you who to reach.
- An alert the day Citius Oncology, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Citius Oncology, Inc., from your own LinkedIn network
Citius Oncology, Inc.
Shareholders voted on something at a meeting. An 8-K is the notice a US public company must file within four business days of a major event.
citiuspharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
Citius Oncology held its 2026 annual stockholder meeting on September 29, 2026, electing three Class II directors and ratifying Wolf & Company, P.C. as the independent auditor. The voting results demonstrated strong shareholder support with over 67 million votes for each director nominee and over 73 million shares supporting the auditor ratification, indicating stable governance and investor confidence.
Key Takeaways
Dr. Eugene Holuka, Robert Smith, and Carol Webb were elected as Class II directors for three-year terms expiring in 2029
Wolf & Company, P.C. was ratified as the independent registered public accounting firm for fiscal year ending September 30, 2026
2 more takeaways
Related Filings (2)
2 more filings from Citius Oncology, Inc. in the last 90 days
Filing Overview
What This Means
Citius Oncology, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.